Crescent Capital BDC- 5% NT REDEEM 25/05/2026 USD 25 (FCRX) has a P/E ratio of 28.71, above the Finance sector average of 16.82.
Get informed when a big investor buys or sells
+ Follow28.71
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Crescent Capital BDC- 5% NT REDEEM 25/05/2026 USD 25 (FCRX) currently reports a P/E ratio of 28.71. That is above the Finance sector average of 16.82. Use the charts on this page to explore Crescent Capital BDC- 5% NT REDEEM 25/05/2026 USD 25's P/E ratio history and peer comparisons.
Crescent Capital BDC- 5% NT REDEEM 25/05/2026 USD 25's P/E ratio of 28.71 is higher than the Finance sector average of 16.82. That is roughly 70.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Crescent Capital BDC- 5% NT REDEEM 25/05/2026 USD 25's market price to a fundamental measure such as earnings, sales, or book value. At 28.71, FCRX can look expensive or cheap only in context — versus its own history, growth rate, and Finance peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of 28.71, then check the historical chart for trend and the peer comparison chart for relative positioning. The Finance average is 16.82. From there, open related valuation or income-statement pages for Crescent Capital BDC- 5% NT REDEEM 25/05/2026 USD 25, and consider following FCRX for alerts when major investors trade the stock.
Crescent Capital BDC- 5% NT REDEEM 25/05/2026 USD 25 is classified in the Finance sector. On P/E ratio, it currently shows 28.71 versus a sector average near 16.82. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Finance are usually more informative than comparing FCRX with unrelated industries.